Year: 2025
Type: article
Abstract: “Early engagement with regulatory bodies is essential to clarify how peptide conjugates will be evaluated.” Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks to Helen Bright, CSO, Centauri Therapeutics, about an immune-stimulating platform that leverages peptide conjugation to enhance immune responses. She discusses the challenges and advantages of this conjugate platform, from achieving regulatory body approval to therapeutic efficacy. Bioconjugation Insights is the only digital content channel that truly provides the ‘big picture’ for this rapidly evolving and expanding field. If you would like to access all of our Open Access content, you can register here.
Source: Bioconjugation Insights
Author: Helen Bright
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4417334122
FWCI:
Cites:
Cited by:
Related to: